RSS Feed
Search Ask-Cato.com
Tags
adverse events biologics biosimilar biotech cancer Cato BioVentures Cato Research CDER clinical investigator clinical research clinical trials CMC conference CROs DIA drug development eCTD efficacy FDA funding GlobalSubmit guidance Health Canada IND in vitro diagnostics labeling manufacturing marketing application medical devices NDA NIH nonclinical research oncology Phase 1 Phase 2 postmarketing protocol regulatory affairs safety statistical analysis toxicology transparency venture capital warning letters webinarCategories
- Clinical Trials (52)
- Conferences and Meetings (34)
- eCTD (26)
- FDA (71)
- Guest Posts (5)
- Health Canada (6)
- Industry News (56)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (36)
- Social Media (6)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (10)
- Webinars (24)
Tag Archives: CROs
Project Management for Biotech Companies
In today’s fast paced, high pressure world of drug development there are multiple factors that can and do affect marketing success. Large organizations understand the value that project management can contribute to a successful project. The smaller companies tend to … Continue reading
Posted in Clinical Trials, Project Management, Regulatory Strategy
Tagged biotech, Cato Research, central labs, clinical investigator, clinical research, clinical trials, CMC, CROs, drug development, drug product, efficacy, enrollment, FDA, GCP, GLP, GMP, ICH, manufacturing, nonclinical research, project management, protocol, safety, site selection, SOP, stability, toxicology
Comments Off
Bridging the Valley of Death: Bringing New Drugs from the Bench to the Clinic
To bring a new medicine to the stage of clinical trial testing requires on the order of $500,000 to one million dollars and then seven to ten years of clinical trials and around $800 million dollars before getting to market. … Continue reading
Posted in Clinical Trials, Venture Capital
Tagged biotech, cancer, Cato BioVentures, clinical trials, CROs, drug development, funding, NIH, Phase 1, Phase 2, preclinical, toxicology, venture capital
Comments Off
Conference Recap – BayBio 2011
The BayBio Annual Conference 2011 was held on 20-21 April 2011 in Burlingame, CA. The event was attended by more than 1,000 San Francisco Bay Area biotech and life sciences professionals from over 400 companies. This year’s conference focused on … Continue reading
Posted in Conferences and Meetings, Venture Capital
Tagged BayBio, biotech, Cato BioVentures, clinical development, CROs, drug candidate, drug development, funding, marketing, nonprofits, Northern California, Orphan Drug Designations, Phase 1, Phase 2, regulatory strategy, risk, safety, venture capital
Comments Off
